Study Assesses Unmet Needs of Cancer Caregivers
the Cancer Therapy Advisor take:
Caregivers report the highest percentage of unmet needs for support in areas regarding fear concerning the patient’s condition, receiving disease-related information, and emotional support for themselves, according to an article published online in Cancer.
A total of 188 dyads of patients diagnosed with lung, urological, or gastrointestinal cancer and their primary caregivers took part in the study’s cross-sectional survey.
Caregivers completed the Supportive Care Needs Survey self-report questionnaire and the patients completed the corresponding questionnaire.
In the questionnaires, both the caregivers and the patients supplied information describing their distress, anxiety, and depression. Medical records provided clinical characteristics of the patients.
The majority (72.3%) of the caregivers was female and their median age was 57.8 years.
Results showed that caregivers were more distressed (P<0.01) and had greater anxiety (P<0.01) scores than the patients.
Furthermore, more caregivers reported having at least 10 unmet needs than no unmet needs (43.6% vs 14.4%, respectively). Unmet needs reported by patients and caregivers’ anxiety predicted unmet needs of caregivers, to some extent.
The study suggests caregivers undergo systematic assessments to examine their unmet needs and determine specific offers for the caregivers.
Caregivers report the highest percentage of unmet needs for support in areas regarding fear concerning the patient’s condition.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC
- Pembrolizumab Alone or With Chemotherapy Prolongs OS in Recurrent/Metastatic HNSCC
- Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma
- Assays May Help Researchers Discover Factors Underlying Immunotherapy Response
- Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer